Immunity Bio (IBRX) is presented as a strong buy due to regulatory approvals, commercial partnerships, and positive technicals, with potential for significant price appreciation.
Source Post
Is Immunitybio Inc IBRX A Good Time To Buy Now? IBRX Stock Analysis
Mar 15, 2026
The podcast discusses Immunity Bio (IBRX), a biotech company pivoting to revenue generation with its oncology drug Anktiva. The analysis highlights recent regulatory approvals in the EU and Saudi Arabia, a strong commercialization strategy through partnerships, and positive technical indicators like a golden cross. Despite risks in clinical execution and competition, the overall sentiment is highly bullish, with price targets suggesting significant upside potential.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
IBRXbuy opened Mar 15, 2026
-16.92%